Near Real-Time Monitoring of Critical Drugs for the Care of Patients with COVID-19

    Basic Details
    Date Posted
    Monday, April 20, 2020
    Status
    In progress
    Description

    This study aims to sequentially monitor priority drugs for the care of patients hospitalized with COVID-19, including sedatives and drugs used to assist with mechanical ventilation, therapies for respiratory diseases, thrombolytics, anticoagulants, anti-infectives, opioid analgesics, and other drugs used to treat COVID-19. Drug utilization in the outpatient care setting will also be examined. The purpose of this activity is to assess changing patterns of use to support regional assessments of drug use and to assess for drug shortages.

    Information
    Time Period
    March 2020 – Current
    Population / Cohort
    All individuals
    Data Source(s)
    Select Sentinel Data Partners
    Workgroup Leader(s)

    Sruthi Adimadhyam, PhD; Judith Maro, PhD; Jeffery Brown, PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

    Michael Nguyen, MD; Grace Chai, PharmD; Corinne Woods, RPh, MPH; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

    Workgroup Member(s)

    Jillian Burk, MPH; Katie Haffenreffer; Meg Her, MPH; Casie Horgan, MPH; Jennifer Noble; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

    Robert Ball, MD, MPH, ScM; Catherine Corey; Gerald Dal Pan, MD, MHS; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD